In a landmark shift for biomedical research, the FDA is phasing out its long-standing requirement for animal testing in the development of monoclonal antibodies and other drugs. Announced in an April 10, 2025 statement, this move reflects growing confidence in advanced non-animal models—such as organoids and other in vitro systems—that more accurately predict human responses to new therapies. Enabled by the FDA Modernization Act of 2022, the policy allows the use of alternatives like cell-based assays and computer modeling to support safety and efficacy assessments during early drug development. It also removes the requirement for animal studies in the approval process for biosimilar or interchangeable biological products.
This change isn’t just regulatory housekeeping—it’s an inflection point. And for researchers, it’s a green light to explore more ethical, scalable, and human-relevant models.
Organoids: The Future, Now
Organoids—3D cellular models that mimic the structure and function of human tissues—are leading the charge in this new era. Unlike traditional 2D cultures or animal models, organoids offer researchers a high-fidelity window into disease biology and drug response, all within a controlled, human-relevant system. From oncology to infectious disease research, organoids are rapidly becoming a preferred tool for translational science.
However, the promise of organoids hinges on one crucial factor: the quality of the sample.
Elevating Organoid Research with Levitation Technology™
At LevitasBio, we recognize that the integrity of your sample can significantly impact the success of an organoid experiment. That’s why we developed the LeviCell® system—to provide researchers with a fast, gentle, and label-free method of cell enrichment that preserves cell viability, phenotype, and function.
For organoid researchers, this means:
- Maximizing starting material: The efficient recovery of fragile, low-viability samples ensures that even rare or precious human subject materials can be utilized for organoid generation.
- Cleaner inputs: Removal of dead cells, debris, and contaminating cells leads to faster, healthier organoid cultures and more meaningful data – leading to better outcomes.
- No interference: Our technology is entirely label-free, eliminating antibody binding or stress that could alter activation states and impact downstream readouts.
A Match for the Moment
As animal testing requirements loosen and organoids gain prominence, LevitasBio is uniquely positioned to facilitate this transition. We’re helping researchers not only meet new regulatory opportunities but push the boundaries of what’s possible in human model systems.
Final Thoughts
The FDA’s decision is more than a policy update—it’s a call to innovate. As researchers respond with organoid-based strategies, LevitasBio is proud to stand at the intersection of precision, scalability, and biological fidelity.
The age of animal-free drug development is here—and it’s time your sample prep caught up.
Explore how LeviCell can elevate your organoid workflows: levitasbio.com
